Volume 19, Issue 4

Neurotherapeutics is now archived and no longer receiving submissions with this publisher. All articles published in the journal during its time with Springer will remain fully searchable through our websites.

Search all Neurotherapeutics articles

July 2022

Motor Neuron Disease Therapy for the 21st Century

Issue Editors:

Nicholas J Maragakis,
Jeffrey D. Rothstein

30 articles in this issue

The Evolving Landscape of Motor Neuron Disease Therapeutics
Nicholas J. Maragakis
Jeffrey D. Rothstein
Editorial 28 September 2022 Pages: 1047 - 1049
Nuclear Pore Dysfunction in Neurodegeneration
Olivia Spead
Benjamin L Zaepfel
Jeffrey D Rothstein
Review 07 September 2022 Pages: 1050 - 1060
Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD
Lindsey R. Hayes
Petr Kalab
Review 05 July 2022 Pages: 1061 - 1084
Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis
Wenxue Li
Darshan Pandya
Avindra Nath
Review Open access 12 April 2022 Pages: 1085 - 1101
Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis
Andrew T. Nelson
Davide Trotti
Review 30 June 2022 Pages: 1102 - 1118
Pathogenic Extracellular Vesicle (EV) Signaling in Amyotrophic Lateral Sclerosis (ALS)
Gloria Kim
Xuan Chen
Yongjie Yang
Review 14 April 2022 Pages: 1119 - 1132
Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy
Michael P. Coleman
Review Open access 07 October 2022 Pages: 1133 - 1144
Antisense Oligonucleotides for the Study and Treatment of ALS
Benjamin D. Boros
Kathleen M. Schoch
Timothy M. Miller
Review 02 June 2022 Pages: 1145 - 1158
Approaches to Gene Modulation Therapy for ALS
Katharina E. Meijboom
Robert H. Brown
Review 06 September 2022 Pages: 1159 - 1179
Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design
Christina N. Fournier
Review 11 July 2022 Pages: 1180 - 1192
Deep Brain Stimulation for Addictive Disorders—Where Are We Now?
Jason Yuen
Abbas Z. Kouzani
Yoonbae Oh
Current Perspectives Open access 11 April 2022 Pages: 1193 - 1215
Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers
Monica Margoni
Paolo Preziosa
Maria A. Rocca
Current Perspectives 06 June 2022 Pages: 1216 - 1228
Deep Brain Stimulation for Depression
Martijn Figee
Patricio Riva-Posse
Brian H. Kopell
Current Perspectives 11 July 2022 Pages: 1229 - 1245
Preventing Amyotrophic Lateral Sclerosis Before It Starts: When to Intervene?
Merit Cudkowicz
Commentary 01 August 2022 Pages: 1246 - 1247
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Michael Benatar
Joanne Wuu
Stephanie Fradette
Original Article Open access 18 May 2022 Pages: 1248 - 1258
Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia Type 3: a Randomized, Double-Blind, Sham-Controlled Trial
Roderick P. P. W. M. Maas
Steven Teerenstra
Bart P. C. van de Warrenburg
Original Article Open access 02 May 2022 Pages: 1259 - 1272
Efficacy of Repetitive Trans-spinal Magnetic Stimulation for Patients with Parkinson’s Disease: a Randomised Controlled Trial
Takao Mitsui
Yoshiharu Arii
Yukiko Kuroda
Original Article 27 June 2022 Pages: 1273 - 1282
Treating Parkinson’s Disease via Activation of BDNF/TrkB Signaling Pathways and Inhibition of Delta-Secretase
Seong Su Kang
Zhourui Wu
Keqiang Ye
Original Article 20 May 2022 Pages: 1283 - 1297
ERRγ Ligand Regulates Adult Neurogenesis and Depression-like Behavior in a LRRK2-G2019S-associated Young Female Mouse Model of Parkinson’s Disease
Hyo In Kim
Juhee Lim
Hyun Jin Choi
Original Article 25 May 2022 Pages: 1298 - 1312
Fluconazole Is Neuroprotective via Interactions with the IGF-1 Receptor
Valerie Toodle
Myoung-Hwa Lee
Joseph P. Steiner
Original Article Open access 13 July 2022 Pages: 1313 - 1328
Improving Gene Therapy for Angelman Syndrome with Secreted Human UBE3A
Austin W. Nenninger
Matthew Willman
Kevin R. Nash
Original Article 09 May 2022 Pages: 1329 - 1339
Clinical and Preclinical Evidence for M₁ Muscarinic Acetylcholine Receptor Potentiation as a Therapeutic Approach for Rett Syndrome
Mackenzie Smith
Bright Arthur
Rocco G. Gogliotti
Original Article Open access 07 June 2022 Pages: 1340 - 1352
Impact of Genetic Testing on Therapeutic Decision-Making in Childhood-Onset Epilepsies—a Study in a Tertiary Epilepsy Center
Allan Bayat
Christina D. Fenger
Danish Cytogenetic Central Registry study group
Original Article 20 June 2022 Pages: 1353 - 1367
Pulsed-Focused Ultrasound Provides Long-Term Suppression of Epileptiform Bursts in the Kainic Acid-Induced Epilepsy Rat Model
Po-Chun Chu
Hsiang-Yu Yu
Hao-Li Liu
Original Article Open access 17 May 2022 Pages: 1368 - 1380
Activation of Double-Stranded RNA–Activated Protein Kinase in the Dorsal Root Ganglia and Spinal Dorsal Horn Regulates Neuropathic Pain Following Peripheral Nerve Injury in Rats
Jian Zhang
Xuan Zhang
Ji-Tian Xu
Original Article 02 June 2022 Pages: 1381 - 1400
Inhibitions and Down-Regulation of Motor Protein Eg5 Expression in Primary Sensory Neurons Reveal a Novel Therapeutic Target for Pathological Pain
Na Wei
Yang Yu
Yao-Qing Yu
Original Article Open access 28 June 2022 Pages: 1401 - 1413
ASENT 2022 Annual Meeting

Abstracts 03 October 2022 Pages: 1414 - 1431
Correction to: Pharmacological Rescue With SR8278, A Circadian Nuclear Receptor REV-ERBα Antagonist As A Therapy for Mood Disorders In Parkinson’s Disease
Jeongah Kim
Inah Park
Kyungjin Kim
Correction Open access 02 May 2022 Pages: 1432 - 1432
Correction to: Luminescent Human iPSC-Derived Neurospheroids Enable Modeling of Neurotoxicity After Oxygen–glucose Deprivation
Elise Van Breedam
Aleksandra Nijak
Peter Ponsaerts
Correction 21 June 2022 Pages: 1433 - 1433
Correction to: A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity
Silke Nuber
Chee Yeun Chung
Robert H. Scannevin
Correction Open access 06 July 2022 Pages: 1434 - 1434

Volume 19, Issue 4

The Evolving Landscape of Motor Neuron Disease Therapeutics

Nuclear Pore Dysfunction in Neurodegeneration

Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD

Retroviral Elements in Pathophysiology and as Therapeutic Targets for Amyotrophic Lateral Sclerosis

Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis

Pathogenic Extracellular Vesicle (EV) Signaling in Amyotrophic Lateral Sclerosis (ALS)

Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy

Antisense Oligonucleotides for the Study and Treatment of ALS

Approaches to Gene Modulation Therapy for ALS

Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design

Deep Brain Stimulation for Addictive Disorders—Where Are We Now?

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers

Deep Brain Stimulation for Depression

Preventing Amyotrophic Lateral Sclerosis Before It Starts: When to Intervene?

Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study

Cerebellar Transcranial Direct Current Stimulation in Spinocerebellar Ataxia Type 3: a Randomized, Double-Blind, Sham-Controlled Trial

Efficacy of Repetitive Trans-spinal Magnetic Stimulation for Patients with Parkinson’s Disease: a Randomised Controlled Trial

Treating Parkinson’s Disease via Activation of BDNF/TrkB Signaling Pathways and Inhibition of Delta-Secretase

ERRγ Ligand Regulates Adult Neurogenesis and Depression-like Behavior in a LRRK2-G2019S-associated Young Female Mouse Model of Parkinson’s Disease

Fluconazole Is Neuroprotective via Interactions with the IGF-1 Receptor

Improving Gene Therapy for Angelman Syndrome with Secreted Human UBE3A

Clinical and Preclinical Evidence for M₁ Muscarinic Acetylcholine Receptor Potentiation as a Therapeutic Approach for Rett Syndrome

Impact of Genetic Testing on Therapeutic Decision-Making in Childhood-Onset Epilepsies—a Study in a Tertiary Epilepsy Center

Pulsed-Focused Ultrasound Provides Long-Term Suppression of Epileptiform Bursts in the Kainic Acid-Induced Epilepsy Rat Model

Activation of Double-Stranded RNA–Activated Protein Kinase in the Dorsal Root Ganglia and Spinal Dorsal Horn Regulates Neuropathic Pain Following Peripheral Nerve Injury in Rats

Inhibitions and Down-Regulation of Motor Protein Eg5 Expression in Primary Sensory Neurons Reveal a Novel Therapeutic Target for Pathological Pain

ASENT 2022 Annual Meeting

Correction to: Pharmacological Rescue With SR8278, A Circadian Nuclear Receptor REV-ERBα Antagonist As A Therapy for Mood Disorders In Parkinson’s Disease

Correction to: Luminescent Human iPSC-Derived Neurospheroids Enable Modeling of Neurotoxicity After Oxygen–glucose Deprivation

Correction to: A Brain-Penetrant Stearoyl-CoA Desaturase Inhibitor Reverses α-Synuclein Toxicity

Navigation